bioRxivCancer BiologyPreprint
MYC/MIZ1 suppression of lysosomal protein degradation drives immune evasion in pancreatic ductal adenocarcinoma
Bastian KrenziD, Toshitha KannaniD, Greta MattavelliiD, Werner SchmitziD, Anneli Gebhardt-Wolf, Mara JohniD, Ana Cetkovic, Arpa AintablianiD, Stella Caviccioli, Lukas Nowak, Sarah Bopp, Christina Schuelein‐Voelk, Carsten Patrick AdeiD, Steffi Herold, Julian BenderiD, Bettina WarscheidiD, Christine SersiD, Magdalena ŻukowskaiD, Martin VaethiD, Gabriele BücheliD, Frédérique ZindyiD, Shondra M. Pruett‐MilleriD, Martine F. RousseliD, Dieter SauriD, Angela RiedeliD, Martin EilersiD
Abstract
The MYC oncoprotein promotes immune evasion of pancreatic ductal adenocarcinoma (PDAC), but the underlying molecular mechanisms are not fully understood. Here we show that MYC protects PDAC tumors from CD4+ T cell-dependent elimination. Single cell sequencing shows that MYC suppression in tumor cells increases amino acid availability and broadly activates amino acid-responsive gene expression programs in immune cell populations. This occurs because MYC-driven uptake depletes free amino acids from tumor interstitial fluid and plasma, while MYC compromises macropinocytosis and autophagy, both of which depend on lysosomal protein degradation. MYC engages the POZ/BTB transcription factor MIZ1 to suppress lysosomal genes regulated by the TFE3/TFEB/MITF network or by free MIZ1, thereby inhibiting lysosomal protein degradation. An orthogonal genetic model enabling transient, selective inhibition of amino acid uptake in tumor cells recapitulates the effects of MYC depletion on amino acid levels in the tumor microenvironment and induces complete, CD4+ T cell-dependent tumor eradication with long-term survival. We propose that MYC-mediated, cell-autonomous disruption of lysosome function coupled to non-cell-autonomous protection from immune clearance allows MYC-low cells to benefit from MYC-high neighbors, such that intratumoral heterogeneity in MYC expression confers a selective advantage to the entire tumor. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=141 SRC="FIGDIR/small/740267v1_ufig1.gif" ALT="Figure 1"> View larger version (53K): org.highwire.dtl.DTLVardef@140d2ccorg.highwire.dtl.DTLVardef@cf5f1borg.highwire.dtl.DTLVardef@6d132aorg.highwire.dtl.DTLVardef@10535e6_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- research focus: cell signaling & trafficking
- research focus: development & morphogenesis
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immune Selection Pressure Contributes to Pancreatic Cancer Immune Evasion
R. Ajina, A. Zuo, … L. M. Weiner·bioRxiv·Jun 15, 2020
- Myc inhibition triggers GM-CSF-driven regression of pancreatic tumours
Tania Campos, Roderik M. Kortlever, … GI EVAN·bioRxiv·Feb 25, 2026
- Progranulin promotes immune evasion of pancreatic adenocarcinoma through regulation of MHCI expression
P. F. Cheung, J. Yang, … J. T. Siveke·bioRxiv·Feb 24, 2021
- Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma
V. Graziano, A. Dannhorn, … D. I. Jodrell·bioRxiv·May 24, 2022
- TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma
Anna D. Louie, Kelsey E. Huntington, … Wafik S. El‐Deiry·American Journal of Cancer ResearchPeer-reviewed·Jan 1, 2025
- The basal cell state maintains pancreatic cancers by controlling an immunosuppressive circuit
Anupriya Singhal, Kate Ryan, … Tuomas Tammela·bioRxiv·Jul 14, 2026